TY - JOUR
T1 - D-dimer diagnostics
T2 - can I use any D-dimer assay? Bridging the knowledge-to-action gap
AU - Selby, Rita
AU - Meijer, Piet
AU - Favaloro, Emmanuel J.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/1
Y1 - 2024/1
N2 - A State of the Art lecture titled “D-dimer Diagnostics: Can I use any D-dimer assay? Bridging the Knowledge-to-Action gap” was presented at the International Society on Thrombosis and Haemostasis Congress in 2023, included in the session on the clinical impact of variability in commonly used coagulation assays. Here, we review the role of D-dimer, primarily in the outpatient diagnosis of patients with venous thromboembolism (VTE) when combined with clinical decision rules. We focus on the recent large management trials that have studied adjustments of VTE exclusion thresholds for D-dimer based on either prior clinical probability of VTE or patient age, and the resultant benefit of reduced imaging for VTE and improved diagnostic efficiency. In this context, we report on the significant variability between D-dimer results and the multiple D-dimer assays in use worldwide using data from international external quality assurance programs. This variability is particularly high at typical VTE exclusion thresholds. We discuss the potential clinical impact of D-dimer assay substitution on accuracy of diagnosis and risk stratification of patients with VTE. Finally, we summarize relevant new data on this topic presented during the 2023 International Society on Thrombosis and Haemostasis Congress and outline future priorities urgently needed to harmonize D-dimer results and reporting that will require international collaboration among multiple stakeholders with an overall goal to close this knowledge-to-action gap.
AB - A State of the Art lecture titled “D-dimer Diagnostics: Can I use any D-dimer assay? Bridging the Knowledge-to-Action gap” was presented at the International Society on Thrombosis and Haemostasis Congress in 2023, included in the session on the clinical impact of variability in commonly used coagulation assays. Here, we review the role of D-dimer, primarily in the outpatient diagnosis of patients with venous thromboembolism (VTE) when combined with clinical decision rules. We focus on the recent large management trials that have studied adjustments of VTE exclusion thresholds for D-dimer based on either prior clinical probability of VTE or patient age, and the resultant benefit of reduced imaging for VTE and improved diagnostic efficiency. In this context, we report on the significant variability between D-dimer results and the multiple D-dimer assays in use worldwide using data from international external quality assurance programs. This variability is particularly high at typical VTE exclusion thresholds. We discuss the potential clinical impact of D-dimer assay substitution on accuracy of diagnosis and risk stratification of patients with VTE. Finally, we summarize relevant new data on this topic presented during the 2023 International Society on Thrombosis and Haemostasis Congress and outline future priorities urgently needed to harmonize D-dimer results and reporting that will require international collaboration among multiple stakeholders with an overall goal to close this knowledge-to-action gap.
KW - D-dimer
KW - diagnosis
KW - external proficiency
KW - quality assurance
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85185817204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185817204&partnerID=8YFLogxK
U2 - 10.1016/j.rpth.2024.102335
DO - 10.1016/j.rpth.2024.102335
M3 - Article
C2 - 38433976
AN - SCOPUS:85185817204
SN - 2475-0379
VL - 8
SP - 1
EP - 10
JO - Research and Practice in Thrombosis and Haemostasis
JF - Research and Practice in Thrombosis and Haemostasis
IS - 1
M1 - 102335
ER -